1. Home
  2. ZCMD vs XBIO Comparison

ZCMD vs XBIO Comparison

Compare ZCMD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$0.11

Market Cap

7.9M

Sector

Real Estate

ML Signal

N/A

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

N/A

Current Price

$3.10

Market Cap

7.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZCMD
XBIO
Founded
2012
N/A
Country
China
United States
Employees
N/A
2
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ZCMD
XBIO
Price
$0.11
$3.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.1M
10.6K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$1.90
52 Week High
$2.29
$13.93

Technical Indicators

Market Signals
Indicator
ZCMD
XBIO
Relative Strength Index (RSI) 12.24 55.58
Support Level N/A $2.94
Resistance Level $0.71 $3.42
Average True Range (ATR) 0.25 0.16
MACD -0.16 0.01
Stochastic Oscillator 1.49 66.89

Price Performance

Historical Comparison
ZCMD
XBIO

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: